News 
Market Data 
Discover
Replies to post #10878 on The Rising Influence of Rising Affluence
10/06/15 9:31 AM
Under the [TPP] deal, countries would give drugmakers at least five years of exclusive access to the clinical data used to win approval for new drugs. An additional several years of regulatory review would likely mean drug companies would have an effective monopoly for about eight years before facing lower-cost, generic competition…
10/06/15 1:11 PM
For steelmakers, auto-parts manufacturers, garment companies and solar panel producers, as well as their hundreds of thousands of workers, one question is whether the gradual reduction of import tariffs and other trade barriers will unintentionally provide a back door for more Chinese goods to enter the United States.
The agreement has elaborate “rules of origin” that determine which goods will qualify for duty-free treatment. In the auto industry, for example, 45 percent of the value of each car or light truck will need to be produced in a Trans-Pacific Partnership country for the vehicle to be charged little or no duty by customs officials.
By comparison, the North American Free Trade Agreement used a different methodology that effectively required 53 percent to 55 percent of the components by net cost to be produced in North America. So the new agreement has the effect of allowing slightly more components to come from outside the trade region, most likely from China.
07/29/16 9:51 PM
